ATE519486T1 - Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer - Google Patents

Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer

Info

Publication number
ATE519486T1
ATE519486T1 AT04790120T AT04790120T ATE519486T1 AT E519486 T1 ATE519486 T1 AT E519486T1 AT 04790120 T AT04790120 T AT 04790120T AT 04790120 T AT04790120 T AT 04790120T AT E519486 T1 ATE519486 T1 AT E519486T1
Authority
AT
Austria
Prior art keywords
inhibitor
pharmaceutical composition
reuppose
composition containing
monoamine neurotransmitter
Prior art date
Application number
AT04790120T
Other languages
German (de)
English (en)
Inventor
Thomas Friedl
Joachim Mierau
Andreas Raschig
Juergen Reess
Joergen Scheel-Krueger
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE519486T1 publication Critical patent/ATE519486T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04790120T 2003-10-16 2004-10-05 Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer ATE519486T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03023635 2003-10-16
EP04005819 2004-03-11
PCT/EP2004/011093 WO2005039580A1 (en) 2003-10-16 2004-10-05 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

Publications (1)

Publication Number Publication Date
ATE519486T1 true ATE519486T1 (de) 2011-08-15

Family

ID=34524707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04790120T ATE519486T1 (de) 2003-10-16 2004-10-05 Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer

Country Status (10)

Country Link
US (2) US20050154009A1 (enExample)
EP (2) EP2269608A3 (enExample)
JP (1) JP2007508336A (enExample)
AT (1) ATE519486T1 (enExample)
AU (1) AU2004283425B2 (enExample)
CA (1) CA2542442C (enExample)
DK (1) DK1675591T3 (enExample)
MX (1) MXPA06003762A (enExample)
NZ (1) NZ547152A (enExample)
WO (1) WO2005039580A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2005039580A1 (en) * 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
BRPI0416691A (pt) * 2003-11-18 2007-01-30 Boehringer Ingelheim Int forma de preparação farmacêutica sólida
CA2553649A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
EP1708707A1 (en) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
EP1755602A1 (en) * 2004-06-04 2007-02-28 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
KR101408488B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
RU2483729C2 (ru) * 2008-05-30 2013-06-10 Нитто Денко Корпорейшн Чрескожно абсорбируемый препарат
EP2279739B2 (en) * 2008-05-30 2018-02-28 Nitto Denko Corporation Donepezil-containing patch preparation and packaging thereof
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR20150118092A (ko) * 2012-11-30 2015-10-21 피2디 인코퍼레이티드 치매 치료를 위한 치환된 벤즈트로핀 유사체들
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
MX2021004737A (es) * 2018-10-24 2021-06-04 Saniona As Composiciones de tropano transdermicas y metodos para usar las mismas.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554626A (en) * 1896-02-11 murphy
AU672052B2 (en) * 1992-12-23 1996-09-19 Neurosearch A/S Antidepressant and antiparkinsonian compounds
AU672644B2 (en) * 1992-12-23 1996-10-10 Neurosearch A/S Aryl substituted heterocyclic compounds
DK154192D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Heterocycliske forbindelser
AU671163B2 (en) * 1992-12-23 1996-08-15 Neurosearch A/S Alkyl substituted heterocyclic compounds
US5554626A (en) * 1992-12-23 1996-09-10 Neurosearch A/S Substituted heterocyclic compounds as dopamine-reuptake inhibitors
CN1043763C (zh) * 1994-04-19 1999-06-23 纽罗研究公司 莨菪烷衍生物及其制备方法和应用
ZA971525B (en) * 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
JP2005508872A (ja) * 2001-05-23 2005-04-07 ニューロサーチ、アクティーゼルスカブ トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法
US20030008791A1 (en) * 2001-06-06 2003-01-09 Lonza Inc. Non-alcoholic hand sanitizer
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
JP2006517567A (ja) * 2003-02-12 2006-07-27 ニューロサーチ、アクティーゼルスカブ 新規8−アザ−ビシクロ[3.2.1]オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法
WO2005039580A1 (en) * 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
EP1708707A1 (en) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
CA2553649A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
EP1755602A1 (en) * 2004-06-04 2007-02-28 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation

Also Published As

Publication number Publication date
DK1675591T3 (da) 2011-11-14
CA2542442C (en) 2012-08-21
EP1675591B1 (en) 2011-08-10
JP2007508336A (ja) 2007-04-05
WO2005039580A1 (en) 2005-05-06
MXPA06003762A (es) 2006-06-14
EP1675591A1 (en) 2006-07-05
AU2004283425A1 (en) 2005-05-06
NZ547152A (en) 2009-12-24
EP2269608A2 (en) 2011-01-05
EP2269608A3 (en) 2011-02-16
US20050154009A1 (en) 2005-07-14
AU2004283425B2 (en) 2010-07-08
CA2542442A1 (en) 2005-05-06
US20100210626A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
ATE432919T1 (de) Azetidinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
JO2371B1 (en) 4-phenyl-pyridine derivatives
ATE495154T1 (de) Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
ATE386725T1 (de) Heterocyclylverbindungen
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
MXPA04003730A (es) Derivados del 3-azabiciclo[3.1.0]hexano.
GB0109122D0 (en) Novel compounds
ATE308522T1 (de) Opioidrezeptorantagonisten
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
DE60208178D1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
ATE398109T1 (de) 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
TW200510370A (en) Urea derivatives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1675591

Country of ref document: EP